In addition, clinical trials of CIMAvax-EGF with Pembrolizumab (k drug) for first-line treatment in patients with advanced NSCLC with high expression of PD-L1 are also ongoing. This evidence concerns the gene CD274 and non-small cell lung carcinoma.